Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEXMAB Study
2024-517444-64-00Phase 2Completed
- Sponsor
- Faron Pharmaceuticals
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of bexmarilimab in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by Faron Pharmaceuticals. Started Oct 2024; status: completed.
02
Drugs
bexmarilimab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-517444-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517444-64-00.